Montag A & Associates Inc. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 422.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 41,515 shares of the medical research company’s stock after acquiring an additional 33,569 shares during the period. Thermo Fisher Scientific comprises about 1.1% of Montag A & Associates Inc.’s portfolio, making the stock its 23rd largest holding. Montag A & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $12,092,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in the company. Private Trust Co. NA lifted its holdings in shares of Thermo Fisher Scientific by 66.7% in the second quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after purchasing an additional 1,310 shares in the last quarter. Fulton Bank N.A. lifted its holdings in shares of Thermo Fisher Scientific by 2.6% in the second quarter. Fulton Bank N.A. now owns 4,423 shares of the medical research company’s stock valued at $1,299,000 after purchasing an additional 110 shares in the last quarter. Swedbank lifted its holdings in shares of Thermo Fisher Scientific by 91.8% in the second quarter. Swedbank now owns 782,855 shares of the medical research company’s stock valued at $229,909,000 after purchasing an additional 374,739 shares in the last quarter. Davis Rea LTD. purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $1,443,000. Finally, Carroll Financial Associates Inc. lifted its holdings in shares of Thermo Fisher Scientific by 9.4% in the second quarter. Carroll Financial Associates Inc. now owns 1,367 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 88.24% of the company’s stock.
Shares of NYSE:TMO traded up $1.11 during midday trading on Friday, hitting $294.65. 787,876 shares of the stock were exchanged, compared to its average volume of 1,323,858. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.23 and a current ratio of 1.80. Thermo Fisher Scientific Inc. has a 52-week low of $208.34 and a 52-week high of $306.00. The business’s fifty day simple moving average is $290.18 and its two-hundred day simple moving average is $283.40. The company has a market capitalization of $117.34 billion, a PE ratio of 26.50, a P/E/G ratio of 1.90 and a beta of 1.14.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The business had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.19 billion. During the same period last year, the company earned $2.62 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 5.9% compared to the same quarter last year. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Tuesday, December 17th will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is 6.83%.
A number of analysts have recently issued reports on the company. Credit Suisse Group restated a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Monday, July 15th. ValuEngine lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Robert W. Baird increased their target price on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Finally, JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $314.45.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 47,729 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the transaction, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at $97,332,684.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now directly owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,833 shares of company stock valued at $15,299,095. 0.45% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: Initial Coin Offering (ICO)
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.